查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1930119

全球子宮頸癌疫苗市場：市場規模、佔有率、成長率、產業分析、依類型、應用和地區劃分的考量因素以及未來預測（2026-2034）

Cervical Cancer Vaccines Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 150 Pages | 商品交期: 請詢問到貨日

價格

子宮頸癌疫苗市場成長因素

近年來，受疾病盛行率上升和全球疫苗接種計畫擴大的推動，全球子宮頸癌疫苗市場呈現強勁成長勢頭。截至2025年，該市場價值達123.6億美元。在公眾意識提高和疫苗接種覆蓋範圍擴大的推動下，預計該市場將在2026年達到141.6億美元，並在2034年達到541億美元，預測期內複合年增長率（CAGR）為18.70%。北美地區在2025年引領全球市場，佔34.50%的市佔率。這主要得益於該地區較高的疫苗接種率和完善的醫療保健基礎設施。

子宮頸癌是全球女性最常見的癌症之一，主要由持續感染高危險型人類乳突病毒 (HPV) 引起。由於免疫反應減弱，感染 HIV 的女性罹患子宮頸癌的風險顯著較高。 HPV 是一種性傳染病，是導致晚期子宮頸癌的主要原因，因此推動了疫苗接種的需求。

市場動態

市場驅動因素

子宮頸癌發生率的上升是市場成長的主要驅動因素。 HPV 感染率的上升、資源匱乏地區意識不足、社會經濟差距、吸菸、人口老化和免疫功能減弱等因素都加劇了疾病負擔。根據世界衛生組織 (WHO) 預測，2022 年全球將新增約 66 萬例子宮頸癌病例，導致約 35 萬人死亡，凸顯了有效疫苗接種計畫的迫切性。 疾病盛行率的不斷上升持續推動著全球子宮頸癌疫苗的普及。

市場限制因子

儘管成長前景強勁，但疫苗猶豫和錯誤訊息對市場擴張構成挑戰。文化偏見、對疫苗安全性的誤解以及諸如青少年接種疫苗會導致不孕等錯誤觀念，導致一些地區的疫苗接種率偏低。根據Ecancer Medical Science於2024年8月發布的報告，迷信和錯誤訊息仍然是子宮頸癌疫苗普及的主要挑戰，尤其是在較保守的社會中。

市場機會

不斷擴大的公私合作關係正在創造新的成長機會。各國政府、非政府組織和製藥公司正在加強合作，透過全球疫苗免疫聯盟（Gavi）、世界衛生組織（WHO）和國際藥品採購機制（Unitaid）等機構主導的倡議，提高服務不足地區的HPV疫苗接種率。 2024年12月，Unitaid和Gavi攜手合作，旨在改善子宮頸癌疫苗的可及性，支持提高公眾意識的項目，並降低疫苗的可負擔性。

市場挑戰

低收入和中等收入國家（LMICs）醫療基礎設施的匱乏構成了重大挑戰。冷鏈維護、電力供應不穩定以及醫療設施有限等問題阻礙了疫苗的分發。根據 "臨床婦產科雜誌" 報導，子宮頸癌仍然是低收入和中等收入國家女性最常見的癌症。此外，HPV DNA篩檢的高成本和基礎設施要求進一步限制了這些地區的市場成長。

市場趨勢

影響市場的顯著趨勢是單劑HPV疫苗的廣泛應用。傳統的兩劑或三劑接種方案往往導致依從性低，尤其是在資源匱乏的地區。單劑疫苗的有效性已得到臨床證實，簡化了疫苗接種方案並提高了覆蓋率。 2022年4月，世界衛生組織免疫策略諮詢專家小組（SAGE）確認，單劑疫苗可提供HPV的有效保護。

其他值得關注的趨勢包括旨在透過男女接種疫苗來降低HPV整體感染率的性別中立疫苗策略，以及國產、價格合理的疫苗的興起。 2023年1月，印度血清研究所推出了該國首款國產HPV疫苗CERVAVAC，顯著提高了疫苗的可及性和可負擔性。

市場區隔分析

依疫苗類型劃分，市場分為預防性疫苗和治療性疫苗。截至2024年，預防性疫苗（目前唯一獲準用於預防子宮頸癌的疫苗）佔市場主導地位。根據世界衛生組織2024年7月報告，治療性疫苗預計將實現最快成長，目前有超過20種候選疫苗正在進行臨床開發。

依技術劃分，分子疫苗因其安全性、有效性和易於生產而佔市場主導地位。這些疫苗利用病毒樣顆粒（VLP）誘發強烈的免疫反應。載體疫苗也因其持久的免疫力而佔了相當大的佔有率。

依分銷管道劃分，醫院藥房在2024年佔主導地位，這主要得益於患者接種疫苗的就診量巨大。政府和機構供應管道也佔了相當大的佔有率，這主要歸功於大規模的公共疫苗接種計劃。

區域展望

北美市場領先，預計在2026年將創造48.5億美元的收入，這主要得益於高疾病流行率和強有力的政府舉措。歐洲憑藉其醫療保健系統和集中化的疫苗採購，佔了第二大市場。亞太地區成為成長最快的地區，這主要得益於子宮頸癌的高發生率以及印度 "終結子宮頸癌使命" 等措施。 由於人們意識的提高和疫苗接種計劃的擴大，預計拉丁美洲和中東及非洲地區將出現穩定增長。

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第四章：關鍵考慮因素

  • 主要國家和地區子宮頸癌盛行率（2025 年）
  • 主要國家及地區監理概況
  • 主要公司產品線分析
  • 主要產業趨勢：併購、業務合作
  • 主要公司新產品發布

第五章 全球子宮頸癌疫苗市場分析：洞察與預測（2021-2034）

  • 市場分析、洞察與預測：依疫苗類型劃分
    • 預防性疫苗
    • 治療性疫苗
  • 市場分析、洞察與預測：依技術劃分
    • 分子生物學疫苗
    • 載體疫苗
    • 其他
  • 市場分析、洞察與預測：依通路劃分
    • 醫院
    • 政府及機構供應
    • 其他
  • 市場分析、洞察與預測：依地區劃分
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東及非洲

第六章 北美子宮頸癌疫苗市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 美國
    • 加拿大

第七章 歐洲子宮頸癌疫苗市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 斯堪的納維亞
    • 歐洲其他地區

第八章 亞太地區子宮頸癌疫苗市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 東南亞
    • 亞太其他地區

第九章：拉丁美洲子宮頸癌疫苗市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區

    第十章：中東與非洲子宮頸癌疫苗市場分析：洞察與預測（2021-2034）

    • 依國家劃分
      • 海灣合作委員會（GCC）國家/地區
      • 南非
      • 中東和非洲其他地區

    第十一章 競爭分析

    • 全球市佔率分析（2025 年）
    • 公司簡介
    • GSK plc.
    • Merck &Co., Inc.
    • Serum Institute of India Pvt. Ltd.
    • THERAVECTYS
    • ViciniVax
    • Walvax Biotechnology Co., Ltd.
    • Xiamen Innovax Biotech CO., LTD.
Product Code: FBI113609

Growth Factors of cervical cancer vaccines Market

The global cervical cancer vaccines market demonstrated strong growth momentum in recent years, driven by increasing disease prevalence and expanding vaccination programs worldwide. In 2025, the market was valued at USD 12.36 billion. With rising awareness and extended immunization coverage, the market is projected to grow to USD 14.16 billion in 2026 and further reach USD 54.1 billion by 2034, registering a CAGR of 18.70% during the forecast period. North America dominated the global market in 2025, accounting for 34.50% market share, supported by high vaccine adoption rates and strong healthcare infrastructure.

Cervical cancer remains one of the most common cancers among women globally and is primarily caused by persistent infection with high-risk human papillomavirus (HPV) strains. Women living with HIV are at significantly higher risk of developing cervical cancer due to weakened immune responses. HPV, a sexually transmitted infection, is the major etiological factor behind progressive cervical cancer cases, increasing the demand for preventive vaccination.

Market Dynamics

Market Drivers

The rising prevalence of cervical cancer is a key driver of market growth. Factors such as increasing HPV incidence, lack of awareness in low-resource settings, socio-economic inequalities, smoking, aging populations, and compromised immune systems contribute to the growing disease burden. According to the World Health Organization (WHO), approximately 660,000 new cervical cancer cases were reported globally in 2022, resulting in around 350,000 deaths, highlighting the urgent need for effective vaccination programs. This growing disease prevalence continues to increase the adoption of cervical cancer vaccines worldwide.

Market Restraints

Despite strong growth prospects, vaccine hesitancy and misinformation present challenges to market expansion. Cultural stigma, misconceptions regarding vaccine safety, and false beliefs-such as infertility risks associated with adolescent vaccination-reduce uptake in several regions. As reported by Ecancer Medical Science in August 2024, myths and misinformation remain major barriers to cervical cancer vaccine adoption, particularly in conservative societies.

Market Opportunities

The expansion of public-private partnerships is creating new growth opportunities. Governments, NGOs, and pharmaceutical companies are increasingly collaborating to improve HPV vaccination coverage in underserved regions through initiatives led by organizations such as Gavi, WHO, and Unitaid. In December 2024, Unitaid and Gavi partnered to enhance access to cervical cancer preventive vaccines, supporting awareness programs and improving vaccine affordability.

Market Challenges

Limited healthcare infrastructure in low- and middle-income countries (LMICs) poses a significant challenge. Issues such as cold-chain maintenance, unreliable electricity supply, and limited access to healthcare facilities restrict vaccine distribution. According to the Journal of Clinical Obstetrics and Gynecology, cervical cancer remains the most common cancer affecting women in LMICs. Additionally, the high cost of HPV DNA screening and infrastructure requirements further constrain market growth in these regions.

Market Trends

A prominent trend shaping the market is the shift toward single-dose HPV vaccination. Traditional two- or three-dose schedules often result in lower compliance, particularly in resource-limited settings. Clinical evidence now supports the effectiveness of a single dose, simplifying immunization programs and improving coverage. In April 2022, WHO's Strategic Advisory Group of Experts on Immunization (SAGE) confirmed that a single dose provides solid protection against HPV.

Other notable trends include gender-neutral vaccination strategies, which aim to reduce overall HPV transmission by vaccinating both boys and girls, and the rise of indigenous and affordable vaccines. In January 2023, the Serum Institute of India launched CERVAVAC, India's first domestically developed HPV vaccine, significantly improving affordability and access.

Segmentation Analysis

By vaccine type, the market is divided into preventive and therapeutic vaccines. Preventive vaccines dominated the market in 2024, as they are currently the only approved option for cervical cancer prevention. Therapeutic vaccines are expected to witness the fastest growth due to more than 20 candidates in clinical development, as reported by WHO in July 2024.

By technology, molecular-based vaccines dominated the market due to their safety, efficacy, and ease of manufacturing. These vaccines utilize virus-like particles (VLPs) to generate strong immune responses. Vector-based vaccines also held a significant share due to their long-lasting immunity.

By distribution channel, hospital pharmacies dominated in 2024, supported by high patient visits for vaccination. Government and organization supply channels also held a substantial share due to large-scale public immunization programs.

Regional Outlook

North America led the market, generating USD 4.85 billion in revenue in 2026, driven by high disease prevalence and strong government initiatives. Europe followed with significant market share due to universal healthcare systems and centralized vaccine procurement. Asia Pacific emerged as the fastest-growing region, supported by high cervical cancer incidence and initiatives such as India's "Cervical Cancer Mukt Bharat" mission. Latin America and the Middle East & Africa are expected to witness steady growth due to rising awareness and expanding vaccination programs.

Competitive Landscape

The market is dominated by GSK plc., Merck & Co., Inc., and Serum Institute of India Pvt. Ltd. GSK's Cervarix and Merck's Gardasil remain widely adopted globally. Companies continue to invest heavily in R&D and therapeutic vaccine development to strengthen their market presence.

Conclusion

The global cervical cancer vaccines market is witnessing robust expansion, driven by the rising burden of cervical cancer, increasing HPV prevalence, and expanding vaccination coverage across developed and emerging regions. Valued at USD 12.36 billion in 2025, the market is projected to reach USD 14.16 billion in 2026 and further grow to USD 54.1 billion by 2034, reflecting strong long-term growth momentum. Preventive vaccines continue to dominate due to their proven efficacy and regulatory approvals, while therapeutic vaccines are gaining traction with a growing clinical pipeline. Technological advancements, particularly molecular-based vaccine platforms, along with trends such as single-dose vaccination, gender-neutral immunization, and the development of affordable indigenous vaccines, are reshaping market dynamics. Although challenges such as vaccine hesitancy and limited healthcare infrastructure in low- and middle-income countries persist, increasing public-private partnerships, government initiatives, and sustained R&D investments by key players are expected to support market expansion throughout the forecast period.

Segmentation By Vaccine Type

  • Preventive Vaccine
  • Therapeutic Vaccine

By Technology

  • Molecular-based
  • Vector-based
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Government & Organization Supply
  • Others

By Region

  • North America (By Vaccine Type, Technology, Distribution Channel, and Country/Sub-region)
    • U.S.
    • Canada
  • Europe (By Vaccine Type, Technology, Distribution Channel, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Vaccine Type, Technology, Distribution Channel, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Vaccine Type, Technology, Distribution Channel, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Vaccine Type, Technology, Distribution Channel, and Country/Sub-region)
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Cervical Cancer, by Key Countries/Region, 2025
  • 4.2. Overview of Regol atory Scenario, by Key Countries/Regions
  • 4.3. Pipeline Analysis, Key Players
  • 4.4. Key Industry Developments - Mergers, Acquisitions, and Partnerships
  • 4.5. New Product Launches, By Key Players

5. Global Cervical Cancer Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Vaccine Type
    • 5.1.1. Preventive Vaccine
    • 5.1.2. Therapeutic Vaccine
  • 5.2. Market Analysis, Insights and Forecast - By Technology
    • 5.2.1. Molecol ar-based
    • 5.2.2. Vector-based
    • 5.2.3. Others
  • 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.3.1. Hospitals
    • 5.3.2. Government & Organization Supply
    • 5.3.3. Others
  • 5.4. Market Analysis, Insights and Forecast - By Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Latin America
    • 5.4.5. Middle East & Africa

6. North America Cervical Cancer Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Vaccine Type
    • 6.1.1. Preventive Vaccine
    • 6.1.2. Therapeutic Vaccine
  • 6.2. Market Analysis, Insights and Forecast - By Technology
    • 6.2.1. Molecol ar-based
    • 6.2.2. Vector-based
    • 6.2.3. Others
  • 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.3.1. Hospitals
    • 6.3.2. Government & Organization Supply
    • 6.3.3. Others
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe Cervical Cancer Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Vaccine Type
    • 7.1.1. Preventive Vaccine
    • 7.1.2. Therapeutic Vaccine
  • 7.2. Market Analysis, Insights and Forecast - By Technology
    • 7.2.1. Molecol ar-based
    • 7.2.2. Vector-based
    • 7.2.3. Others
  • 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.3.1. Hospitals
    • 7.3.2. Government & Organization Supply
    • 7.3.3. Others
  • 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.4.1. U.K.
    • 7.4.2. Germany
    • 7.4.3. France
    • 7.4.4. Spain
    • 7.4.5. Italy
    • 7.4.6. Scandinavia
    • 7.4.7. Rest of Europe

8. Asia Pacific Cervical Cancer Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Vaccine Type
    • 8.1.1. Preventive Vaccine
    • 8.1.2. Therapeutic Vaccine
  • 8.2. Market Analysis, Insights and Forecast - By Technology
    • 8.2.1. Molecol ar-based
    • 8.2.2. Vector-based
    • 8.2.3. Others
  • 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.3.1. Hospitals
    • 8.3.2. Government & Organization Supply
    • 8.3.3. Others
  • 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.4.1. Japan
    • 8.4.2. China
    • 8.4.3. India
    • 8.4.4. Australia
    • 8.4.5. Southeast Asia
    • 8.4.6. Rest of Asia Pacific

9. Latin America Cervical Cancer Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Vaccine Type
    • 9.1.1. Preventive Vaccine
    • 9.1.2. Therapeutic Vaccine
  • 9.2. Market Analysis, Insights and Forecast - By Technology
    • 9.2.1. Molecol ar-based
    • 9.2.2. Vector-based
    • 9.2.3. Others
  • 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.3.1. Hospitals
    • 9.3.2. Government & Organization Supply
    • 9.3.3. Others
  • 9.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 9.4.1. Brazil
    • 9.4.2. Mexico
    • 9.4.3. Rest of Latin America

10. Middle East & Africa Cervical Cancer Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Vaccine Type
    • 10.1.1. Preventive Vaccine
    • 10.1.2. Therapeutic Vaccine
  • 10.2. Market Analysis, Insights and Forecast - By Technology
    • 10.2.1. Molecol ar-based
    • 10.2.2. Vector-based
    • 10.2.3. Others
  • 10.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.3.1. Hospitals
    • 10.3.2. Government & Organization Supply
    • 10.3.3. Others
  • 10.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 10.4.1. GCC
    • 10.4.2. South Africa
    • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. GSK plc.
      • 11.2.1.1. Overview
      • 11.2.1.2. Products
      • 11.2.1.3. Financials (Based on Availability)
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. SWOT,Etc.
    • 11.2.2. Merck & Co., Inc.
      • 11.2.2.1. Overview
      • 11.2.2.2. Products
      • 11.2.2.3. Financials (Based on Availability)
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. SWOT,Etc.
    • 11.2.3. Serum Institute of India Pvt. Ltd.
      • 11.2.3.1. Overview
      • 11.2.3.2. Products
      • 11.2.3.3. Financials (Based on Availability)
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. SWOT,Etc.
    • 11.2.4. THERAVECTYS
      • 11.2.4.1. Overview
      • 11.2.4.2. Products
      • 11.2.4.3. Financials (Based on Availability)
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. SWOT,Etc.
    • 11.2.5. ViciniVax
      • 11.2.5.1. Overview
      • 11.2.5.2. Products
      • 11.2.5.3. Financials (Based on Availability)
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. SWOT,Etc.
    • 11.2.6. Walvax Biotechnology Co., Ltd.
      • 11.2.6.1. Overview
      • 11.2.6.2. Products
      • 11.2.6.3. Financials (Based on Availability)
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. SWOT,Etc.
    • 11.2.7. Xiamen Innovax Biotech CO., LTD.
      • 11.2.7.1. Overview
      • 11.2.7.2. Products
      • 11.2.7.3. Financials (Based on Availability)
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. SWOT,Etc.

List of Tables

  • Table 1: Global Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, by Vaccine Type, 2021-2034
  • Table 2: Global Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, by Technology, 2021-2034
  • Table 3: Global Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 4: Global Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 5: North America Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, by Vaccine Type, 2021-2034
  • Table 6: North America Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, by Technology, 2021-2034
  • Table 7: North America Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 8: North America Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 9: Europe Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, by Vaccine Type, 2021-2034
  • Table 10: Europe Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, by Technology, 2021-2034
  • Table 11: Europe Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 12: Europe Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 13: Asia Pacific Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, by Vaccine Type, 2021-2034
  • Table 14: Asia Pacific Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, by Technology, 2021-2034
  • Table 15: Asia Pacific Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 16: Asia Pacific Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 17: Latin America Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, by Vaccine Type, 2021-2034
  • Table 18: Latin America Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, by Technology, 2021-2034
  • Table 19: Latin America Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 20: Latin America Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: Middle East & Africa Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, by Vaccine Type, 2021-2034
  • Table 22: Middle East & Africa Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, by Technology, 2021-2034
  • Table 23: Middle East & Africa Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 24: Middle East & Africa Cervical Cancer Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Cervical Cancer Vaccines Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Cervical Cancer Vaccines Market Value Share (%), by Vaccine Type, 2025 & 2034
  • Figure 3: Global Cervical Cancer Vaccines Market Value Share (%), by Technology, 2025 & 2034
  • Figure 4: Global Cervical Cancer Vaccines Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 5: Global Cervical Cancer Vaccines Market Value Share (%), by Region, 2025 & 2034
  • Figure 6: North America Cervical Cancer Vaccines Market Value (USD billion), by Vaccine Type, 2025 & 2034
  • Figure 7: North America Cervical Cancer Vaccines Market Value Share (%), by Vaccine Type, 2025
  • Figure 8: North America Cervical Cancer Vaccines Market Value (USD billion), by Technology, 2025 & 2034
  • Figure 9: North America Cervical Cancer Vaccines Market Value Share (%), by Technology, 2025
  • Figure 10: North America Cervical Cancer Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 11: North America Cervical Cancer Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 12: North America Cervical Cancer Vaccines Market Value (USD billion), By Country, 2025 & 2034
  • Figure 13: North America Cervical Cancer Vaccines Market Value Share (%), By Country, 2025
  • Figure 14: Europe Cervical Cancer Vaccines Market Value (USD billion), by Vaccine Type, 2025 & 2034
  • Figure 15: Europe Cervical Cancer Vaccines Market Value Share (%), by Vaccine Type, 2025
  • Figure 16: Europe Cervical Cancer Vaccines Market Value (USD billion), by Technology, 2025 & 2034
  • Figure 17: Europe Cervical Cancer Vaccines Market Value Share (%), by Technology, 2025
  • Figure 18: Europe Cervical Cancer Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 19: Europe Cervical Cancer Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 20: Europe Cervical Cancer Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 21: Europe Cervical Cancer Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 22: Asia Pacific Cervical Cancer Vaccines Market Value (USD billion), by Vaccine Type, 2025 & 2034
  • Figure 23: Asia Pacific Cervical Cancer Vaccines Market Value Share (%), by Vaccine Type, 2025
  • Figure 24: Asia Pacific Cervical Cancer Vaccines Market Value (USD billion), by Technology, 2025 & 2034
  • Figure 25: Asia Pacific Cervical Cancer Vaccines Market Value Share (%), by Technology, 2025
  • Figure 26: Asia Pacific Cervical Cancer Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 27: Asia Pacific Cervical Cancer Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 28: Asia Pacific Cervical Cancer Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 29: Asia Pacific Cervical Cancer Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 30: Latin America Cervical Cancer Vaccines Market Value (USD billion), by Vaccine Type, 2025 & 2034
  • Figure 31: Latin America Cervical Cancer Vaccines Market Value Share (%), by Vaccine Type, 2025
  • Figure 32: Latin America Cervical Cancer Vaccines Market Value (USD billion), by Technology, 2025 & 2034
  • Figure 33: Latin America Cervical Cancer Vaccines Market Value Share (%), by Technology, 2025
  • Figure 34: Latin America Cervical Cancer Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 35: Latin America Cervical Cancer Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 36: Latin America Cervical Cancer Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 37: Latin America Cervical Cancer Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 38: Middle East & Africa Cervical Cancer Vaccines Market Value (USD billion), by Vaccine Type, 2025 & 2034
  • Figure 39: Middle East & Africa Cervical Cancer Vaccines Market Value Share (%), by Vaccine Type, 2025
  • Figure 40: Middle East & Africa Cervical Cancer Vaccines Market Value (USD billion), by Technology, 2025 & 2034
  • Figure 41: Middle East & Africa Cervical Cancer Vaccines Market Value Share (%), by Technology, 2025
  • Figure 42: Middle East & Africa Cervical Cancer Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 43: Middle East & Africa Cervical Cancer Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 44: Middle East & Africa Cervical Cancer Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 45: Middle East & Africa Cervical Cancer Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 46: Global Cervical Cancer Vaccines Market Share (%), By Company, 2025